Sanofi and Alnylam conclude research and option phase of 2014 rare disease alliance
- Details
- Category: Sanofi
Sanofi and Alnylam have agreed to conclude the research and option phase of the companies' 2014 RNAi therapeutics alliance in rare genetic diseases. The material collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiran, as previously announced, will continue unchanged.
Boehringer Ingelheim enhances oncology R&D with novel MacroDel delivery technology via acquisition of ICD Therapeutics
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim announced that it acquired ICD Therapeutics. The acquisition includes rights to ICD's innovative MacroDel biologics-delivery platform. Boehringer Ingelheim will employ this platform for the development of novel therapeutics in collaboration with nanoPET Pharma GmbH, a former shareholder of ICD Therapeutics.
Novartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM Tre
- Details
- Category: Novartis
Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC focused on developing anti-inflammatory medicines targeting the NLRP3 inflammasome.
Selumetinib granted US Breakthrough Therapy Designation in neurofibromatosis type 1
- Details
- Category: AstraZeneca
AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the MEK 1/2 inhibitor and potential new medicine selumetinib.
AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
- Details
- Category: Novartis
AveXis, a Novartis company, today announced it signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont, Colorado, further expanding AveXis' production capacity as it prepares to launch Zolgensma® (onasemnogene abeparvovec-xioi[1]) an investigational gene therapy awaiting global regulatory approvals for the treatment of spinal muscular atrophy (SMA) Type 1 and for future gene therapy treatments in development.
Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
- Details
- Category: Novartis
Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis, including secondary progressive multiple sclerosis (SPMS) with active disease, relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS)*.
Forxiga approved in Japan for type-1 diabetes
- Details
- Category: AstraZeneca
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). The approval is based on data from the Phase III DEPICT clinical programme and a dedicated trial in Japanese patients (D1695C00001).
More Pharma News ...
- Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD
- Bayer reaches settlement to resolve Xarelto™ litigation
- Pfizer secures exclusive option to acquire gene therapy company Vivet Therapeutics
- Bayer is taking collaboration with health care start-ups to the next level
- FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
- Merck to collaborate with GenScript to accelerate cell and gene therapy industrialization in China
- US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis